NEWS RELEASEAustralia, 11 May 2006AUDIO BROADCAST – Acceleration...

NEWS RELEASE
Australia, 11 May 2006
AUDIO BROADCAST – Acceleration of Overseas Expansion
Visiomed Group Ltd wishes to inform the market of an audio broadcast with Dr. William Dolphin, Chief
Executive Officer who will be discussing recent company activities.
The presentation is available at www.boardroomradio.com at 11:30 AM EST on 11th May 2006
- ENDS –
For further information, please contact Visiomed’s CEO Dr William Dolphin on (08) 9321 2712.
About Visiomed Group Ltd
Visiomed (www.visiomed.com.au) develops and commercialises innovative medical technologies for improved
medication delivery and adherence in patients suffering from chronic respiratory diseases.
About the Funhaler®
The Funhaler® is a paediatric incentive spacer for the effective delivery of asthma drugs, developed in Australia.
The Funhaler incorporates auditory and visual incentive modules that provide user feedback and assist in
developing and maintaining proper inhalation technique. The product was designed to improve adherence by
encouraging children to take their asthma medication in accordance with clinical prescriptions. Approximately 8-
15% of children in the US and EU are prescribed asthma medication. Adherence to regular preventer medication
in this age group is known to be poor.
Published, peer-reviewed clinical studies have shown that use of the Funhaler® increases adherence and
delivery of asthma medication; moreover, both children and their parents prefer the Funhaler® to other spacers
and to the use of asthma medication “puffers” alone. Additional, long term clinical studies involving the Funhaler®
are currently under way with support of a $1 million grant from the US National Institutes of Health.
The Funhaler® has been cleared by the US Food and Drug Administration and is covered by international
patents issued and pending. The coverage extends to protection of a wide range of alternative incentive modules
and complimentary applications.
The Funhaler® asthma spacer is CE marked for the EU, FDA cleared for the US and TGA registered
in Australia.